Ipilimumab: Clinical Trials

831 trials of Ipilimumab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

367 completed, 130 active not recruiting, 118 terminated, 109 recruiting. 497 Phase 2, 334 Phase 1, 79 Phase 3, 11 Early Phase 1, 8 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 2497Completed 200, Active not recruiting 88, Terminated 73, Recruiting 70, Unknown 27, Withdrawn 24, Not yet recruiting 12, Suspended 3
Phase 1334Completed 150, Terminated 63, Active not recruiting 42, Recruiting 42, Withdrawn 17, Unknown 13, Not yet recruiting 4, Suspended 3
Phase 379Completed 42, Active not recruiting 16, Recruiting 9, Not yet recruiting 4, Unknown 4, Terminated 2, Suspended 1, Withdrawn 1
Early Phase 111Completed 6, Active not recruiting 2, Terminated 2, Recruiting 1
Not applicable8Completed 4, Recruiting 3, Not yet recruiting 1
Phase 46Completed 3, Active not recruiting 1, Recruiting 1, Terminated 1

Follow Ipilimumab: new trials by email Literature Review of Ipilimumab trials Research Report on Ipilimumab

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.
Nivolumab & Ipilimumab, Nivolumab + Ipilimumab - Advanced Kidney Cancer
Phase 3Not yet recruitingGuliz Ozgun1422027-02-012026-10-01
A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer
Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab), Investigator Choice Chemotherapy (for example docetaxel with or without ramucirumab, gemcitabine, or other National Comprehensive Cancer Network (NCCN)-recommended treatments), Ablative Hypofractionated Radiotherapy - Non-Small Cell Lung Cancer, Metastatic Lung Cancer
Phase 2RecruitingUniversity of Chicago392026-12-122026-06-16
iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma
iSCIB1+, Nivolumab & Ipilimumab, Placebo - Melanoma (Skin Cancer), Advanced Melanoma
Phase 3Not yet recruitingScancell Ltd5502026-12-012026-09-11
Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer
Personalized cancer vaccine including : DNA neoantigen vaccine, MVA viral vector and Ipilimumab (anti-CTLA4) - Metastatic Colorectal Cancer (CRC), Locally Advanced Colorectal Cancer
Phase 1Not yet recruitingCentre Georges Francois Leclerc772026-11-012026-05-14
Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or Older
Anakinra, Biospecimen Collection, Computed Tomography - Melanoma
Phase 1Not yet recruitingUniversity of Southern California402026-11-012026-09-24
NIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCC
Nivolumab, Ipilimumab, Repeat Hepatectomy - Hepatocellular Carcinoma (HCC), Recurrent Hepatocellular Cancer
Phase 2Not yet recruitingShanghai Zhongshan Hospital352026-11-012026-11-05
A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
DNAJB1-PRKACA Peptide Vaccine, DRP-104, Nivolumab - Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))
Phase 1RecruitingSidney Kimmel Comprehensive Cancer Center at Johns Hopkins272026-10-282026-10-30
Adjuvant/Neoadjuvant Immunotherapy in Melanoma Based on Serial Plasma ctDNA Monitoring
Nivolumab, Ipilimumab, Haystack MRD ctDNA Assay - Melanoma
Phase 2RecruitingH. Lee Moffitt Cancer Center and Research Institute562026-10-212026-11-10
A Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab for Advanced Renal Cancer
Ivonescimab (dose level 1) combined with Cadonilimab, Ivonescimab (dose level 2) combined with Cadonilimab, Ivonescimab combined with Ipilimumab - Renal Cell Carcinoma, Clear Cell
Phase 2Not yet recruitingSummit Therapeutics1002026-10-192026-10-16
Neoadjuvant Chemoradiotherapy Plus PD-1 Blockade ± CTLA-4 Blockade for High-Risk Locally Advanced Rectal Cancer (pMMR/MSS): A National Multicenter, Prospective, Randomized Controlled Trial
Ipilimumab & Sintilimab, Sintilimab - Locally Advanced Rectal Cancer (LARC)
Phase 2 / Phase 3Not yet recruitingYao Hongwei1202026-10-012026-10-19
Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma
Ipilimumab, Nivolumab - Melanoma
Phase 2WithdrawnUniversity of Utah2026-10-012026-10-19
Neoadjuvant Chemoradiotherapy Plus PD-1 Blockade ± CTLA-4 Blockade for Low/Intermediate-Risk Locally Advanced Rectal Cancer (pMMR/MSS): A National Multicenter, Prospective, Randomized Controlled Trial
Ipilimumab & Sintilimab, Sintilimab - Locally Advanced Rectal Cancer (LARC)
Phase 2 / Phase 3Not yet recruitingYao Hongwei1202026-10-012026-10-19
Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)
Stereotactic Body Radiation Therapy (SBRT), Pembrolizumab, Nivolumab - Head and Neck Cancer, Non-Small Cell Lung Cancer
Phase 2RecruitingMark Bernard352026-09-092026-10-14
Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy
BreakVax, Ipilimumab 2.5 mg, Pembrolizumab - Glioblastoma (GBM)
Phase 1 / Phase 2Not yet recruitingBreakBio Corp102026-09-012026-08-19
Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II Study
Sintilimab, ipilimumab, Radscopal Radiotherapy - Nasopharyngeal Carcinoma (NPC), Metastatic Nasopharyngeal Carcinoma
Phase 2Not yet recruitingSun Yat-sen University282026-09-012026-08-10
PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma
Cemiplimab, Lpilimumab, Fianlimab - Melanoma
Phase 2Not yet recruitingM.D. Anderson Cancer Center202026-09-012026-04-06
Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy
BreakVax, Ipilimumab 2.5 mg, Pembrolizumab - Triple-Negative Breast Cancer (TNBC)
Phase 1 / Phase 2Not yet recruitingBreakBio Corp102026-09-012026-08-19
Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases
Bevacizumab, Ipilimumab, Nivolumab - Melanoma Brain Metastases
Phase 1 / Phase 2RecruitingMelanoma and Skin Cancer Trials Limited462026-08-312026-10-13
Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma
Nivolumab, Ipilimumab (3 mg/kg) - Hepatocellular Carcinoma (HCC)
Phase 2RecruitingUniversity of Texas Southwestern Medical Center602026-08-212026-08-25
NeoAdjuvant, Spare-Adjuvant (NASA) in Stage IIIB-IV (M1a) Melanoma
Pembrolizumab, Ipilimumab plus nivolumab - Melanoma (Skin Cancer), Melanoma Stage Stage IIIB
Phase 2RecruitingUNC Lineberger Comprehensive Cancer Center552026-08-062026-09-30

Showing 20 of 831. Sign in to see all of them.

Conditions studied

Melanoma (254)  ·  Carcinoma, Non-Small-Cell Lung (88)  ·  Carcinoma, Renal Cell (64)  ·  Neoplasm Metastasis (55)  ·  Neoplasms (52)  ·  Prostatic Neoplasms (35)  ·  Lung Neoplasms (32)  ·  Uveal Melanoma (30)  ·  Carcinoma, Hepatocellular (28)  ·  Pancreatic Neoplasms (28)  ·  Brain Neoplasms (24)  ·  Colorectal Neoplasms (24)  ·  Sarcoma (22)  ·  Breast Neoplasms (20)  ·  Kidney Neoplasms (19)

Sponsors

Bristol-Myers Squibb (141)  ·  National Cancer Institute (NCI) (65)  ·  M.D. Anderson Cancer Center (49)  ·  H. Lee Moffitt Cancer Center and Research Institute (18)  ·  Memorial Sloan Kettering Cancer Center (17)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (17)  ·  The Netherlands Cancer Institute (16)  ·  Dana-Farber Cancer Institute (15)  ·  NYU Langone Health (8)  ·  Emory University (7)  ·  Gustave Roussy, Cancer Campus, Grand Paris (7)  ·  Massachusetts General Hospital (7)  ·  Abramson Cancer Center at Penn Medicine (6)  ·  Washington University School of Medicine (6)  ·  AIO-Studien-gGmbH (5)

Countries

United States (595)  ·  France (120)  ·  Spain (104)  ·  Canada (99)  ·  Germany (98)  ·  Italy (97)  ·  Australia (88)  ·  United Kingdom (83)  ·  Netherlands (72)  ·  Poland (65)  ·  Belgium (62)  ·  China (47)  ·  Switzerland (43)  ·  Japan (41)  ·  Denmark (38)

Top investigators

Steven A. Rosenberg, MD, PhD (5)  ·  Eric Jonasch, MD (3)  ·  Frank S Hodi (3)  ·  John E. Janik, MD (3)  ·  Lawrence Fong, MD (3)  ·  Michael Postow, MD (3)  ·  Sumanta K Pal (3)  ·  A P Chen (2)  ·  Ahmad Tarhini (2)  ·  Ahmad Tarhini, MD, PhD (2)

Results publications

PMID 25667295, PMID 36648215, PMID 24695685, PMID 25649350, PMID 39504507, PMID 35383907, PMID 42836590, PMID 21917607, PMID 24577748, PMID 24844912, PMID 25891173, PMID 29489427, PMID 32376721, PMID 32691060, PMID 33001135, PMID 33058158, PMID 33362722, PMID 33558721, PMID 33735809, PMID 34503735, PMID 34663559, PMID 34855329, PMID 35031545, PMID 36450385, PMID 36989829, PMID 37146227, PMID 37328287, PMID 39369790, PMID 39378385, PMID 39437804, PMID 40614118, PMID 42579028, PMID 12826605, PMID 16087944, PMID 16283570, PMID 16882708, PMID 18523152, PMID 18974373, PMID 19139884, PMID 19156911, PMID 20004617, PMID 20082117, PMID 20525992, PMID 20842054, PMID 21106722, PMID 21639810, PMID 21911310, PMID 22123319, PMID 22326922, PMID 22456429

NIH funding

2016 (23), 2017 (19), 2018 (19), U10CA180820 (11), 2023 (10), U10CA180821 (10), 2014 (8), 2015 (7), 2025 (7), U10CA180868 (7), U10CA180888 (7), UM1CA186691 (6), 2019 (5), P30CA033572 (5), P30CA138292 (5)